{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+High+Grade+B-Cell+Lymphoma&page=3",
    "query": {
      "condition": "Refractory High Grade B-Cell Lymphoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 160,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+High+Grade+B-Cell+Lymphoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+High+Grade+B-Cell+Lymphoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T03:36:46.146Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02199184",
      "title": "Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AIDS-Related Burkitt Lymphoma",
        "Atypical Burkitt/Burkitt-Like Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Burkitt Lymphoma",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Burkitt Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 14,
      "start_date": "2015-01-14",
      "completion_date": "2023-02-17",
      "has_results": true,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02199184"
    },
    {
      "nct_id": "NCT05672251",
      "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Grade 3b Follicular Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma",
        "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Recurrent Transformed Chronic Lymphocytic Leukemia",
        "Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Grade 3b Follicular Lymphoma",
        "Refractory High Grade B-Cell Lymphoma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory Transformed Chronic Lymphocytic Leukemia",
        "Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Loncastuximab Tesirine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mosunetuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2024-01-02",
      "completion_date": "2027-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05672251"
    },
    {
      "nct_id": "NCT01742988",
      "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Relapsed Lymphoma",
        "Refractory Lymphoma",
        "Relapsed and/or Refractory Lymphoma",
        "Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)",
        "Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Double-hit Lymphoma (DHL)",
        "Triple-hit Lymphoma (THL)",
        "Double-expressor Lymphoma (DEL)",
        "High-grade B-cell Lymphoma (HGBL)"
      ],
      "interventions": [
        {
          "name": "fimepinostat",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Curis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2012-12",
      "completion_date": "2020-10-09",
      "has_results": false,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01742988"
    },
    {
      "nct_id": "NCT05507541",
      "title": "TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent ALK Positive Large B-Cell Lymphoma",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation",
        "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent Grade 3b Follicular Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent Intravascular Large B-Cell Lymphoma",
        "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type",
        "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Refractory ALK Positive Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation",
        "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory Grade 3b Follicular Lymphoma",
        "Refractory High Grade B-Cell Lymphoma",
        "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory Intravascular Large B-Cell Lymphoma",
        "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type",
        "Refractory Primary Mediastinal Large B-Cell Lymphoma",
        "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Recurrent Gray Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ontorpacept",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Maplirpacept",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-04-19",
      "completion_date": "2027-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Rochester, Minnesota",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05507541"
    },
    {
      "nct_id": "NCT00363272",
      "title": "Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Burkitt Lymphoma",
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Choroid Plexus Tumor",
        "Childhood Craniopharyngioma",
        "Childhood Grade I Meningioma",
        "Childhood Grade II Meningioma",
        "Childhood Grade III Meningioma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Low-grade Cerebral Astrocytoma",
        "Childhood Spinal Cord Neoplasm",
        "Childhood Supratentorial Ependymoma",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Brain Tumor",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ispinesib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00363272"
    },
    {
      "nct_id": "NCT06343311",
      "title": "T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Non-Hodgkin's Lymphoma (NHL)",
        "Lymphoma, Non-Hodgkins",
        "Lymphomas Non-Hodgkin's B-Cell",
        "Non-Hodgkin Lymphoma",
        "Non-Hodgkin's Lymphoma",
        "Large B-Cell Lymphoma",
        "Lymphoma, Non-Hodgkin's, Adult",
        "Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Relapsed Non-Hodgkin Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "HIV Associated Lymphoma",
        "CNS Lymphoma",
        "High-grade B-cell Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "EB103",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Estrella Immunopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2024-06-01",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Cleveland, Ohio • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06343311"
    },
    {
      "nct_id": "NCT00006125",
      "title": "Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "2000-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 75,
      "location_summary": "Anniston, Alabama • La Jolla, California • San Diego, California + 54 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006125"
    },
    {
      "nct_id": "NCT03793140",
      "title": "A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "CPI-613",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2018-12-31",
      "completion_date": "2026-08-25",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Boston, Massachusetts • Basking Ridge, New Jersey + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03793140"
    },
    {
      "nct_id": "NCT00002663",
      "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "EBV-induced Lymphomas",
        "EBV-associated Malignancies",
        "Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma"
      ],
      "interventions": [
        {
          "name": "Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Atara Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 58,
      "start_date": "1995-03",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2023-02-13",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002663"
    },
    {
      "nct_id": "NCT00003335",
      "title": "Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "Up to 54 Years"
      },
      "enrollment_count": 44,
      "start_date": "1998-01",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-10-05T03:36:46.146Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003335"
    }
  ]
}